Compare EQ & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQ | TMCI |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.4M | 120.4M |
| IPO Year | 2018 | 2021 |
| Metric | EQ | TMCI |
|---|---|---|
| Price | $2.52 | $3.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 6 |
| Target Price | ★ $8.00 | $4.77 |
| AVG Volume (30 Days) | ★ 1.0M | 821.2K |
| Earning Date | 05-25-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $41,095,000.00 | ★ $212,690,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.59 |
| 52 Week Low | $0.37 | $1.17 |
| 52 Week High | $3.54 | $7.78 |
| Indicator | EQ | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 47.58 |
| Support Level | $2.36 | $3.84 |
| Resistance Level | $2.61 | $4.67 |
| Average True Range (ATR) | 0.24 | 0.30 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 18.87 | 16.11 |
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.